Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$123.98

1.66 (1.36%)

04:57
12/14/17
12/14
04:57
12/14/17
04:57

GW Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Salveen Richter upgraded GW Pharmaceuticals to Buy and raised his price target for the shares to $174 from $124. The British biopharmaceutical company closed yesterday up $1.66 to $123.98. Recent clobazam drug-drug interaction data showing independent and synergistic Epidiolex activity addresses a key investor concern, Richter tells investors in a research note. The analyst's checks with key opinion leaders indicate substantial interest in Epidiolex adoption and off-label use in children and adults, which he believes bodes well for the launch. He models for 2025 worldwide peak sales of $2.2B and sees multiple pipeline catalysts in 2018.

GWPH GW Pharmaceuticals
$123.98

1.66 (1.36%)

10/03/17
MZHO
10/03/17
NO CHANGE
Target $51
MZHO
Buy
Zogenix price target raised to $51 from $28 at Mizuho
Mizuho analyst Difei Yang raised his price target for Zogenix (ZGNX) to $51 from $28 after it announced positive topline data for its pivotal phase III trial of ZX008 in Dravet Syndrome - Study 1. The analyst notes study 1 met its primary endpoint, with topline results indicating a clear dose response, efficacy appears better than GW Pharma's (GWPH) Epidiolex, and mechanism of action involving Sig-1R receptor could explain the higher specificity of ZX-008. Yang argues that these findings may allow ZX-008 to be positioned before Epidiolex as a treatment option for Dravet Syndrome patients. He reiterates a Buy rating on Zogenix's shares.
11/20/17
STFL
11/20/17
NO CHANGE
Target $55
STFL
Buy
Physicians expressed excitement for Zogenix epilepsy treatment, says Stifel
After hosting a panel to discuss new developments for rare epileptic conditions, Stifel analyst Annabel Samimy noted that physicians in the space said they believed there was a place for both Zogenix's (ZGNX) fenfluramine and GW Pharmaceuticals' (GWPH) Epidiolex, the two most advanced treatments for Dravet Syndrome and Lennox-Gastaut Syndrome. Excitement for their introductions was "palpable, particularly for fenfluramine," added Samimy, who has a Buy rating and $55 price target on Zogenix and does not cover GW Pharmaceuticals.
11/21/17
CANT
11/21/17
NO CHANGE
Target $208
CANT
Overweight
Abstracts put GW's drug-drug interaction issue to rest, says Cantor
Cantor Fitzgerald analyst Elemer Piros says the American Epilepsy Society published last night 20 abstracts detailing the safety/efficacy of GW Pharmaceuticals' Epidiolex in a multitude of controlled trials and refractory epilepsy indications. GW and collaborators "finally laid the somewhat common concern to rest: does the drug work partly or solely due to a boosting effect on another anti-epileptic drug commonly used, Clobazam?" Piros tells investors in a research note. He believes the answer is "partly." The bear thesis of Epidiolex working "solely" through boosting Clobazam's efficacy has been qualitatively debunked by management before, and now there are numbers to back it up, the analyst adds. He expects a potential approval for Epidiolex in April 2018. Piros has an Overweight rating on GW Pharmaceuticals with a $208 price target. The stock in premarket trading is up $5.23 to $120.00.
12/05/17
CANT
12/05/17
NO CHANGE
Target $208
CANT
Overweight
GW shares still 'significantly undervalued,' says Cantor Fitzgerald
Following the company's fiscal 2017 results, Cantor Fitzgerald analyst Elemer Piros says shares of GW Pharmaceuticals remain "significantly undervalued" based on Epidiolex's opportunity in treating orphan pediatric epileptic conditions. The analyst notes that before the end of 2017, the FDA will announce whether GW's New Drug Application filing has been accepted for review. Piros keeps an Overweight rating on the shares with a $208 price target.

TODAY'S FREE FLY STORIES

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
SF Fed's Williams is being considered for the Vice Chair spot »

SF Fed's Williams is…

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
Breaking General news story  »

Atlanta Federal Reserve…

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

08:29
01/19/18
01/19
08:29
01/19/18
08:29
Hot Stocks
AstraZeneca reports Fasenra receives approval in Japan »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

SYF

Synchrony

$37.30

-0.76 (-2.00%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Technical Analysis
Technical Take: Synchrony falls after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SM

SM Energy

$25.69

-0.93 (-3.49%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Conference/Events
SM Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

SBNY

Signature Bank

$153.44

5.39 (3.64%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Signature Bank analyst commentary  »

Signature Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$61.84

0.67 (1.10%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

, STRA

Strayer

$92.18

-0.64 (-0.69%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Strayer to host special shareholder meeting »

Special shareholder…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

STRA

Strayer

$92.18

-0.64 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

EXEL

Exelixis

$27.86

0.37 (1.35%)

, IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Exelixis and Ipsen co-host a financial community briefing »

Exelixis and Ipsen…

EXEL

Exelixis

$27.86

0.37 (1.35%)

IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

OCUL

Ocular Therapeutix

$5.54

-0.02 (-0.36%)

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Upgrade
Ocular Therapeutix rating change  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Conference/Events
Federal Reserve Bank of Atlanta President speaks at breakfast meeting »

Federal Reserve Bank of…

IBM

IBM

$169.12

0.47 (0.28%)

08:23
01/19/18
01/19
08:23
01/19/18
08:23
Recommendations
IBM analyst commentary  »

IBM price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:22
01/19/18
01/19
08:22
01/19/18
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$203.27

0.12 (0.06%)

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$67.67

0.12 (0.18%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.48

-0.63 (-0.82%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$104.69

-0.09 (-0.09%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

$83.06

0.08 (0.10%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Conference/Events
Lincoln National to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

XLB

S&P Select Materials SPDR

$62.90

-0.04 (-0.06%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.